A Phase III Clinical Trial of Buserelin versus Danazol in the Treatment of Endometriosis

W Matta; Robert W. Shaw

doi:10.1007/978-94-009-2169-6_5

A Phase III Clinical Trial of Buserelin versus Danazol in the Treatment of Endometriosis

W Matta, Robert W. Shaw

In: GnRH Analogues in Cancer and Human Reproduction · 1990 · pp. 39–42 · doi:10.1007/978-94-009-2169-6_5 · W4249545935

book-chapter OA: closed CC0

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens. 1986

References (5)

Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens. via openalex
W170259557 via openalex
W1997894565 via openalex
W2408619637 via openalex
W2477008945 via openalex

Source provenance

openalex: last seen: 2026-06-10T17:14:06.276822+00:00

License: CC0 · commercial use OK

[1] Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens. 1986